Market Place
Sourcing Support
ZyVersa Therapeutic Publishes IC 100 Data Showing Stroke Protection
20 Nov 2024 //
GLOBENEWSWIRE
ZyVersa Therapeutics Reports Q3 2024 Results & Update
14 Nov 2024 //
GLOBENEWSWIRE
ZyVersa Highlights Data on Inflammasome Inhibition in Diabetes
05 Nov 2024 //
GLOBENEWSWIRE
ZyVersa Highlights Need for Therapies for Inflammation in Obesity
29 Oct 2024 //
GLOBENEWSWIRE
ZyVersa Highlights Data Linking Obesity To Neuroinflammation
22 Oct 2024 //
GLOBENEWSWIRE
ZyVersa CEO, Issues Letter to Highlights Obesity Plans For ASC IC 100
17 Oct 2024 //
GLOBENEWSWIRE
ZyVersa CEO Featured On The Big Biz Show To Discuss Obesity Drugs
15 Oct 2024 //
GLOBENEWSWIRE
ZyVersa Reports Q2 2024 Results And Provides Business Update
09 Aug 2024 //
GLOBENEWSWIRE
ZyVersa Announces Published Data Supporting IC 100 For Chronic Inflammation
07 Aug 2024 //
GLOBENEWSWIRE
ZyVersa Reports ASC As Potential Biomarker For Cognitive Changes
29 Jul 2024 //
GLOBENEWSWIRE
ZyVersa Selects Obesity As Lead Indication For IC 100
25 Jul 2024 //
GLOBENEWSWIRE
ZyVersa CEO To Speak At H.C. Wainwright Kidney Conference
09 Jul 2024 //
GLOBENEWSWIRE
ZyVersa Reports Full Year 2023 Financial Results and Provides Business Update
25 Mar 2024 //
GLOBENEWSWIRE
ZyVersa Announces IRB Approval of Phase 2a Trial Protocol to Evaluate VAR 200
18 Mar 2024 //
GLOBENEWSWIRE
ZyVersa taps George Clinical to run kidney disease trial
21 Dec 2023 //
FIERCE BIOTECH
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology
01 Nov 2023 //
GLOBENEWSWIRE
ZyVersa Announces Publication Substantiating VAR 200™s Rationale
11 Oct 2023 //
GLOBENEWSWIRE
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
24 Jul 2023 //
GLOBENEWSWIRE
ZyVersa Announces Publication in Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18
17 Jul 2023 //
GLOBENEWSWIRE
ZyVersa`s CEO, Stephen C. Glover, Is an Speaker at H.C. Wainwright Conference
14 Jul 2023 //
GLOBENEWSWIRE
European Patent Granted for ZyVersa`s Asset, Cholesterol Efflux Mediator VAR 200
07 Jul 2023 //
GLOBENEWSWIRE
ZyVersa Publishes White Paper Detailing Critical Role of Inflammasome ASC
13 Jun 2023 //
GLOBENEWSWIRE
European Patent Office to Grant ZyVersa Patent Application for VAR 200
06 Jun 2023 //
GLOBENEWSWIRE
ZyVersa Announces a Publication in Frontiers in Medicine
25 May 2023 //
GLOBENEWSWIRE
ZyVersa Therapeutics Announces Changes to ZyVersa Board of Directors
19 May 2023 //
GLOBENEWSWIRE
ZyVersa Announces Article Published in Metabolism to Glomerular Cholesterol
15 May 2023 //
GLOBENEWSWIRE
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
12 May 2023 //
GLOBENEWSWIRE
ZyVersa`s CEO, Stephen C. Glover, to Participate in A.G.P. Healthcare Conference
11 May 2023 //
GLOBENEWSWIRE
ZyVersa Therapeutics` CEO, Stephen C. Glover, to Participate in the 2023 BIO
09 May 2023 //
GLOBENEWSWIRE
ZyVersa Adds Dr. Douglas Golenbock to Scientific Advisory Board
24 Apr 2023 //
GLOBENEWSWIRE
ZyVersa Therapeutics CEO, Stephen C. Glover to Appear on Benzinga `All Access`
12 Apr 2023 //
GLOBENEWSWIRE
ZyVersa`s CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase
11 Apr 2023 //
GLOBENEWSWIRE
ZyVersa Announces Article Published in Brain Pathology
10 Apr 2023 //
GLOBENEWSWIRE
ZyVersa Reports Fourth Quarter and Year-End 2022 Financial Results
03 Apr 2023 //
GLOBENEWSWIRE
ZyVersa Reports Employment Inducement Grants Under Nasdaq Rule 5635(c)(4)
13 Mar 2023 //
GLOBENEWSWIRE
ZyVersa Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board
07 Mar 2023 //
GLOBENEWSWIRE
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
27 Feb 2023 //
GLOBENEWSWIRE
ZyVersa Announces Publication Showing IC 100 Reduces Inflammasome Activation
23 Feb 2023 //
GLOBENEWSWIRE
ZyVersa Reports Inducement Grant to CMO Under Nasdaq Listing Rule 5635(c)(4)
27 Jan 2023 //
GLOBENEWSWIRE
ZyVersa Therapeutics to Present at BIO CEO & Investor Conference
25 Jan 2023 //
GLOBENEWSWIRE
ZyVersa Therapeutics CEO, Stephen C. Glover, to Present at Investor Companies
11 Jan 2023 //
GLOBENEWSWIRE
ZyVersa` CEO, Stephen C. Glover, to Participate in the 41st Annual J.P. Morgan
20 Dec 2022 //
PR NEWSWIRE
Stephen C. Glover, & Karen A. Cashmere, are Invited Speakers at Summit
22 Nov 2022 //
PRNEWSWIRE
SEC Declares Form S-4 Registration Statement Effective for Business Combination
15 Nov 2022 //
PRNEWSWIRE
ZyVersa Therapeutics` CEO, Stephen C. Glover, Is Invited Speaker BioFlorida
28 Oct 2022 //
PRNEWSWIRE
ZyVersa and Larkspur Announce Business Combination, Interim Financing
27 Sep 2022 //
PRNEWSWIRE
Data on ZyVersa`s IC 100, Is Effective in Reducing Brain Inflammation
22 Aug 2022 //
PRNEWSWIRE
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4
15 Aug 2022 //
PRNEWSWIRE
ZyVersa`s Proprietary Inflammasome ASC Inhibitor`s Differentiated MoA Featured
03 Aug 2022 //
PRNEWSWIRE
ZyVersa and University of Miami Awarded Grant from The Michael J. Fox Foundation
27 Jul 2022 //
PRNEWSWIRE
ZyVersa Tx to Become Publicly Traded Company via Merger with Larkspur Health
20 Jul 2022 //
PRNEWSWIRE
ZyVersa CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics
09 Sep 2021 //
PRNEWSWIRE
ZyVersa`s CEO Stephen C. Glover to Speak at the H.C. Wainwright Conference
07 Sep 2021 //
PRNEWSWIRE
ZyVersa`s CEO, Stephen C. Glover to Present at 2nd Annual LifeSci Partners
15 Jul 2021 //
PR NEWSWIRE
ZyVersa ` CSO, Nicholas A. LaBella, Jr., to Present at the 3rd Annual CKD
26 Feb 2021 //
PRNEWSWIRE
